<p>Curis Inc. has announced updated clinical data from its ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104). The study is evaluating the addition of emavusertib (CA-4948), an orally available IRAK4 and FLT3 inhibitor, to the combination of venetoclax and azacitidine in AML patients who have achieved complete remission on venetoclax and azacitidine but remain measurable residual disease positive (MRD+). The updated results, presented in a poster at the 67th ASH Annual Meeting, showed that 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD) following the addition of emavusertib. The study included cohorts receiving emavusertib for either 7 or 14 days in a 28-day treatment cycle. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curis Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE42152) on December 09, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

CRIS

<p>Curis Inc. announced updated clinical data from its AML triplet study, showing a 62.5% undetectable MRD rate. The study evaluates emavusertib added to venetoclax and azacitidine in AML patients. Results were presented at the 67th ASH Annual Meeting, with 5 of 8 patients achieving undetectable MRD. The study includes cohorts receiving emavusertib for 7 or 14 days in a 28-day cycle.</p>

Curis Reports 62.5% Undetectable MRD Rate in Frontline AML Triplet Study